CADL - CIK 0001841387
Candel Therapeutics, Inc. trades as CADL. This page tracks Candel Therapeutics, Inc. through 382 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -14144.0% to -15035.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| SCHEDULE 13G/A | - | 2026-04-27 |
The largest companies sharing Candel Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
In its latest fiscal year Candel Therapeutics, Inc. reported a net loss of $38.18M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.